Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Warrant (NQ: BIAFW )

0.6000 +0.1101 (+22.47%)
Streaming Delayed Price Updated: 3:21 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,066
Open 0.6930
Bid (Size) 0.2000 (100)
Ask (Size) 0.7308 (1)
Prev. Close 0.4899
Today's Range 0.6000 - 0.6930
52wk Range 0.0460 - 0.9000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
+433.81%
+433.81%
1 Month
-21.05%
-21.05%
3 Month
+736.82%
+736.82%
6 Month
+1074.17%
+1074.17%
1 Year
+167.26%
+167.26%

More News

Read More
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies News Update
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies In The News
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies In the News
From bioAffinity Technologies
Via Business Wire
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
From bioAffinity Technologies, Inc.
Via Business Wire
CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
From bioAffinity Technologies, Inc.
Via Business Wire
AMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Presents Research Findings at CYTO 2023
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.